Literature DB >> 19105777

Xoft Axxent electronic brachytherapy.

Adam Dickler1, Kambiz Dowlatshahi.   

Abstract

Balloon-based brachytherapy was developed to render accelerated partial-breast irradiation more accessible to breast cancer patients. Xoft Axxent electronic brachytherapy (eBX) is a novel method of accelerated partial-breast irradiation that utilizes an electronic source to produce x-rays. eBX does not require a high dose rate afterloader unit or a shielded vault and, thus, may appeal to a larger number of patients undergoing the accelerated partial-breast irradiation procedure. eBX is associated with a lower radiation dose to normal tissues and larger 'hot spots' than treatment with the MammoSite device. Additional applications are also being developed for eBX, including endometrial cancer treatment.

Entities:  

Mesh:

Year:  2009        PMID: 19105777     DOI: 10.1586/17434440.6.1.27

Source DB:  PubMed          Journal:  Expert Rev Med Devices        ISSN: 1743-4440            Impact factor:   3.166


  4 in total

1.  Measurements and simulations of focused beam for orthovoltage therapy.

Authors:  Hassan Abbas; Dip N Mahato; Jahangir Satti; C A MacDonald
Journal:  Med Phys       Date:  2014-04       Impact factor: 4.071

2.  Multihelix rotating shield brachytherapy for cervical cancer.

Authors:  Hossein Dadkhah; Yusung Kim; Xiaodong Wu; Ryan T Flynn
Journal:  Med Phys       Date:  2015-11       Impact factor: 4.071

3.  Treatment of cervical cancer with electronic brachytherapy.

Authors:  Sergio Lozares-Cordero; José Antonio Font-Gómez; Almudena Gandía-Martínez; Anabela Miranda-Burgos; Agustina Méndez-Villamón; David Villa-Gazulla; Verónica Alba-Escorihuela; Sara Jiménez-Puertas; Víctor González-Pérez
Journal:  J Appl Clin Med Phys       Date:  2019-06-11       Impact factor: 2.102

4.  Preclinical Evaluation of Intraoperative Low-Energy Photon Radiotherapy Using Spherical Applicators in Locally Advanced Prostate Cancer.

Authors:  François Buge; Sophie Chiavassa; Chloé Hervé; Jérôme Rigaud; Grégory Delpon; Stéphane Supiot
Journal:  Front Oncol       Date:  2015-09-15       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.